Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Non-Small-Cell Lung

Explore clinical trials studying Carcinoma, Non-Small-Cell Lung. Study availability and eligibility vary by location and protocol.

440 public trials 56 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Non-Small-Cell Lung trial results

Completed

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

NCT03037385

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Bronchial Diseases, +55 more
Locations
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • UC Irvine Medical Center Orange, California, United States
  • University of Colorado Anschutz Medical Campus Aurora, Colorado, United States
  • Georgetown University Medical Center Washington D.C., District of Columbia, United States
View all 71 locations
View Trial Details
Completed

A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT04075396

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations
  • City of Hope Duarte, California, United States
  • Advent Health Orlando Orlando, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Montefiore Medical Center The Bronx, New York, United States
View Trial Details
Completed

An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

NCT01853826

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations
  • The Prince of Wales Hospital Randwick, New South Wales, Australia
  • Sunshine Hospital AT Albans, Victoria, Australia
  • St John of God Murdoch Murdoch, Western Australia, Australia
  • Medical University of Graz State Hospital - University Hospital Graz Graz, Austria
View all 118 locations
View Trial Details
Completed

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

NCT02489903

Conditions
Adnexal Diseases, Bronchial Neoplasms, Carcinoma, +31 more
Locations
  • Stanford University Palo Alto, California, United States
  • VA Connecticut Cancer Center West Haven, Connecticut, United States
  • Memorial Hospital of South Bend South Bend, Indiana, United States
  • Baptist Health Lexington, Kentucky, United States
View Trial Details
Completed

Afatinib in NSCLC With HER2 Mutation

NCT02597946

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations
  • Hunan Province Tumor Hospital Changsha, China
  • First Affiliated Hospital of Guangzhou Medical University Guangzhou, China
  • Zhejiang Cancer Hospital Hangzhou, China
  • The Second Affiliated Hospital to Nanchang University Nanchang, China
View Trial Details
Completed

Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)

NCT03669523

Conditions
Bone Metastases, Bronchial Neoplasms, Carcinoma, Bronchogenic, +8 more
Locations
  • CH du Pays d'Aix Aix-en-Provence, France
  • Chu Angers Angers, France
  • Centre Hospitalier de Beauvais Beauvais, France
  • Centre Hospitalier Fleyriat Bourg-en-Bresse, France
View all 27 locations
View Trial Details
Completed

A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.

NCT01346540

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations
  • 1199.82.39004 Boehringer Ingelheim Investigational Site Milan, Italy
  • 1199.82.3102 Boehringer Ingelheim Investigational Site Maastricht, Netherlands
  • 1199.82.3401 Boehringer Ingelheim Investigational Site Barcelona, Spain
  • 1199.82.3406 Boehringer Ingelheim Investigational Site Madrid, Spain
View Trial Details
Completed

Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy

NCT02300298

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations
  • 1199.90.81001 Boehringer Ingelheim Investigational Site Chiba , Kashiwa, Japan
  • 1199.90.81003 Boehringer Ingelheim Investigational Site Kanagawa, Yokohama, Japan
  • 1199.90.81007 Boehringer Ingelheim Investigational Site Osaka, Osakasayama, Japan
  • 1199.90.81006 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan
View Trial Details

Related conditions